Search: (hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Odontologi)) pers:(Hakeberg Magnus)
> (2000-2004) >
The effect of a den...
-
Coli, Pierluigi,1964Gothenburg University,Göteborgs universitet,Odontologiska institutionen,Institute of Odontology
(author)
The effect of a dentifrice in the prevention of recurrent aphthous stomatitis.
- Article/chapterEnglish2004
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/55475
-
https://gup.ub.gu.se/publication/55475URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-4442URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
PURPOSE: A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the efficacy of an experimental dentifrice on the prevention of recurrent aphthous stomatitis (RAS). MATERIAL AND METHODS: A 3-month pretrial period was used to self-record data pertaining to the frequency, ulcer size, duration, and pain associated with ulcers. Thirty-six participants, who reported at least 3 RAS episodes or 30 days with RAS during the pretrial period, completed the study. Following a stratified randomization for age, sex and disease severity, the participants received the experimental dentifrice (T) or the placebo (C). The test period comprised 3 months of self-evaluation of number of ulcers, size and location. Pain related to RAS was estimated by the use of a Visual Analogue Scale (VAS). RESULTS: Symptoms were found to decrease in both groups when the pretrial and test periods were compared, although no statistical difference was reached in the C group. A statistically significant difference between the two time periods was obtained for the T group concerning the number of days with ulcers (p < 0.025) and VAS (p < 0.010). Of more clinical importance was the observation that 50% of the patients in the T group reported a more than 50% reduction in days with ulcers compared to 17% in the C group. CONCLUSIONS: The dentifrice may be used as a treatment strategy for a subgroup of patients with RAS in view of the low adverse effects and the benefit of using a treatment modality that is a part of daily routines.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Jontell, Mats,1951Gothenburg University,Göteborgs universitet,Odontologiska institutionen,Institute of Odontology(Swepub:gu)xjonma
(author)
-
Hakeberg, Magnus,1954Jönköping University,Gothenburg University,Göteborgs universitet,Odontologiska institutionen,Institute of Odontology,HHJ, Avdelningen för naturvetenskap och biomedicin,HHJ. Centrum för oral hälsa(Swepub:hj)hakm
(author)
-
Göteborgs universitetOdontologiska institutionen
(creator_code:org_t)
Related titles
-
In:Oral health & preventive dentistry2:2, s. 133-411602-1622
Internet link
Find in a library
To the university's database